Trial Profile
A Phase 2 Study of Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Burosumab (Primary)
- Indications Fibrous dysplasia of bone; Hypophosphataemia
- Focus Therapeutic Use
- 27 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2022 Planned initiation date (estimated date for recruitment of the first subject) changed to 22 Dec 2022.
- 06 Dec 2022 Status changed from not yet recruiting to recruiting.